Cell Signaling Technology Announces Expansion of Studies with AstraZeneca to Evaluate CST’s PhosphoScan® Platform for Kinase Inhibitor Phosphoproteomic Profiling
Beverly, MA, January 9, 2006 – Cell Signaling Technology, Inc. (CST) announced today a second agreement with AstraZeneca under which an expanded pilot study will be performed with CST’s PhosphoScan® technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds. CST’s PhosphoScan® proteomics technology is a patent-pending strategy that enables the discovery of drug target phospho-profiles (Phospho-Signatures®) in cells and disease tissues. The PhosphoScan® technology involves immunoaffinity purification and mass spectroscopy and was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The Phospho-Signatures® discovered with PhosphoScan® may enable biomarker assays for target validation and therapeutic kinase inhibitor clinical development.
“Our expanded PhosphoScan® research program with AstraZeneca illustrates the value of CST’s phosphoproteomics capabilities to our partner, and we are confident that the program deliverables will continue to add value to AstraZeneca’s kinase inhibitor development programs,” said Christopher Bunker, CST’s Director of Pharma Services. “With PhosphoScan®, we can deliver focused, in-depth Phospho-Signatures® of kinase inhibitor response in disease cells and tissues, and identify biomarkers of kinase target activation and inhibition. AstraZeneca can also benefit, under our agreement, from CST’s expertise in antibody and immunoassay development to translate PhosphoScan® discoveries into clinical biomarker assays.”
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. PhosphoScan® leverages CST’s core capabilities in antibody development to deliver unparalleled insight into cellular phosphorylation profiles enabling more efficient and informative kinase drug discovery and clinical development. CST is commercializing the PhosphoScan® technology through research alliances and licensing opportunities. Information on CST can be obtained at the Company’s website at www.cellsignal.com